Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott G Williams

Showing results (31-40 of 105) with videos related to

Pageof 11
Sort By:
Brachytherapy|November 23, 2006
A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?Johann I Tang, Scott G Williams, Keen Hun Tai, et al.
Molecular Plant-Microbe Interactions : MPMI|December 16, 2005
Genetic analysis of developmentally regulated resistance to downy mildew (Hyaloperonospora parasitica) in Arabidopsis thalianaJohn M McDowell, Scott G Williams, Nicholas T Funderburg, et al.
Lancet (London, England)|August 9, 2021
Prostate cancerShahneen Sandhu, Caroline M Moore, Edmund Chiong, et al.
International Journal of Radiation Oncology, Biology, Physics|May 30, 2006
A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systemsScott G Williams, Tom Pickles, Larry Kestin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 23, 2008
Urethral stricture following high dose rate brachytherapy for prostate cancerLisa Sullivan, Scott G Williams, Keen Hun Tai, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2003
What defines intermediate-risk prostate cancer? Variability in published prognostic modelsScott G Williams, Jeremy L Millar, Michael J Dally, et al.
Endocrine Oncology (Bristol, England)|February 5, 2024
The GLP-1 receptor is expressed <i>in vivo</i> by human metastatic prostate cancerMark S Stein, Victor Kalff, Scott G Williams, et al.
Medical Physics|January 15, 2024
Towards optimal heterogeneous prostate radiotherapy dose prescriptions based on patient-specific or population-based biological featuresYutong Zhao, Annette Haworth, Hayley M Reynolds, et al.
International Journal of Radiation Oncology, Biology, Physics|October 31, 2007
Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performanceScott G Williams, Mark K Buyyounouski, Tom Pickles, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 7, 2004
Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapyScott G Williams, Jeremy L Millar, Gillian M Duchesne, et al.
Pageof 11

Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
Brachytherapy|November 23, 2006
A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?Johann I Tang, Scott G Williams, Keen Hun Tai, et al.
Molecular Plant-Microbe Interactions : MPMI|December 16, 2005
Genetic analysis of developmentally regulated resistance to downy mildew (Hyaloperonospora parasitica) in Arabidopsis thalianaJohn M McDowell, Scott G Williams, Nicholas T Funderburg, et al.
Lancet (London, England)|August 9, 2021
Prostate cancerShahneen Sandhu, Caroline M Moore, Edmund Chiong, et al.
International Journal of Radiation Oncology, Biology, Physics|May 30, 2006
A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systemsScott G Williams, Tom Pickles, Larry Kestin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 23, 2008
Urethral stricture following high dose rate brachytherapy for prostate cancerLisa Sullivan, Scott G Williams, Keen Hun Tai, et al.
International Journal of Radiation Oncology, Biology, Physics|December 31, 2003
What defines intermediate-risk prostate cancer? Variability in published prognostic modelsScott G Williams, Jeremy L Millar, Michael J Dally, et al.
Endocrine Oncology (Bristol, England)|February 5, 2024
The GLP-1 receptor is expressed <i>in vivo</i> by human metastatic prostate cancerMark S Stein, Victor Kalff, Scott G Williams, et al.
Medical Physics|January 15, 2024
Towards optimal heterogeneous prostate radiotherapy dose prescriptions based on patient-specific or population-based biological featuresYutong Zhao, Annette Haworth, Hayley M Reynolds, et al.
International Journal of Radiation Oncology, Biology, Physics|October 31, 2007
Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performanceScott G Williams, Mark K Buyyounouski, Tom Pickles, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 7, 2004
Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapyScott G Williams, Jeremy L Millar, Gillian M Duchesne, et al.
Pageof 11